228 related articles for article (PubMed ID: 37367727)
1. Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort.
Abdullahi A; Kida IM; Maina UA; Ibrahim AH; Mshelia J; Wisso H; Adamu A; Onyemata JE; Edun M; Yusuph H; Aliyu SH; Charurat M; Abimiku A; Abeler-Dorner L; Fraser C; Bonsall D; ; Kemp SA; Gupta RK
J Antimicrob Chemother; 2023 Aug; 78(8):2000-2007. PubMed ID: 37367727
[TBL] [Abstract][Full Text] [Related]
2. Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.
Tzou PL; Rhee SY; Descamps D; Clutter DS; Hare B; Mor O; Grude M; Parkin N; Jordan MR; Bertagnolio S; Schapiro JM; Harrigan PR; Geretti AM; Marcelin AG; Shafer RW;
J Antimicrob Chemother; 2020 Jan; 75(1):170-182. PubMed ID: 31617907
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review.
Chu C; Tao K; Kouamou V; Avalos A; Scott J; Grant PM; Rhee SY; McCluskey SM; Jordan MR; Morgan RL; Shafer RW
Viruses; 2024 Mar; 16(3):. PubMed ID: 38543764
[TBL] [Abstract][Full Text] [Related]
4. Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.
Vavro C; Ruel T; Wiznia A; Montañez N; Nangle K; Horton J; Buchanan AM; Stewart EL; Palumbo P
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0164521. PubMed ID: 34694878
[TBL] [Abstract][Full Text] [Related]
5. Genotypic correlates of resistance to the HIV-1 strand transfer integrase inhibitor cabotegravir.
Rhee SY; Parkin N; Harrigan PR; Holmes S; Shafer RW
Antiviral Res; 2022 Dec; 208():105427. PubMed ID: 36191692
[TBL] [Abstract][Full Text] [Related]
6. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
[TBL] [Abstract][Full Text] [Related]
7. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
Ndashimye E; Avino M; Olabode AS; Poon AFY; Gibson RM; Li Y; Meadows A; Tan C; Reyes PS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ
J Antimicrob Chemother; 2020 Dec; 75(12):3525-3533. PubMed ID: 32853364
[TBL] [Abstract][Full Text] [Related]
8. Primary resistance against integrase strand transfer inhibitors in integrase strand transfer inhibitor-naive patients failing first- and second-line ART in Tanzania.
Henerico S; Lyimo E; Makubi AN; Magesa D; Desderius B; Mueller A; Changalucha J; Kalluvya SE; Van Zyl G; Preiser W; Mshana SE; Kasang C
J Antimicrob Chemother; 2022 Oct; 77(11):3138-3143. PubMed ID: 36101479
[TBL] [Abstract][Full Text] [Related]
9. Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review.
Tao K; Rhee SY; Chu C; Avalos A; Ahluwalia AK; Gupta RK; Jordan MR; Shafer RW
Viruses; 2023 Sep; 15(9):. PubMed ID: 37766338
[No Abstract] [Full Text] [Related]
10. Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe.
de Salazar A; Viñuela L; Fuentes A; Teyssou E; Charpentier C; Lambert-Niclot S; Serrano-Conde E; Pingarilho M; Fabeni L; De Monte A; Stefic K; Perno CF; Aguilera A; Falces I; Delgado R; Fernandes S; Diogo I; Gomes P; Paraskevis D; Santoro MM; Ceccherini-Silberstein F; Marcelin AG; Garcia F
Clin Infect Dis; 2023 May; 76(9):1628-1635. PubMed ID: 36571282
[TBL] [Abstract][Full Text] [Related]
11. Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.
Brenner BG; Thomas R; Blanco JL; Ibanescu RI; Oliveira M; Mesplède T; Golubkov O; Roger M; Garcia F; Martinez E; Wainberg MA
J Antimicrob Chemother; 2016 Jul; 71(7):1948-53. PubMed ID: 27029845
[TBL] [Abstract][Full Text] [Related]
12. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.
Mesplède T; Osman N; Wares M; Quashie PK; Hassounah S; Anstett K; Han Y; Singhroy DN; Wainberg MA
J Antimicrob Chemother; 2014 Oct; 69(10):2733-40. PubMed ID: 24917583
[TBL] [Abstract][Full Text] [Related]
13. Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART.
Derache A; Iwuji CC; Danaviah S; Giandhari J; Marcelin AG; Calvez V; de Oliveira T; Dabis F; Pillay D; Gupta RK
J Antimicrob Chemother; 2019 Feb; 74(2):473-479. PubMed ID: 30380053
[TBL] [Abstract][Full Text] [Related]
14. Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings.
Semengue ENJ; Armenia D; Inzaule S; Santoro MM; Dambaya B; Takou D; Teto G; Nka AD; Yagai B; Fabeni L; Chenwi C; Angong Beloumou G; Djupsa Ndjeyep SC; Colizzi V; Perno CF; Ceccherini-Silberstein F; Fokam J
J Antimicrob Chemother; 2021 Apr; 76(5):1277-1285. PubMed ID: 33501504
[TBL] [Abstract][Full Text] [Related]
15. Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa.
Salou M; Butel C; Comlan AS; Konou AA; Tegueni K; Ehlan A; Lack F; Dossim S; Ayouba A; Delaporte E; Dagnra AY; Peeters M
AIDS; 2020 Apr; 34(5):783-787. PubMed ID: 31895149
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of the genetic mechanisms of dolutegravir resistance.
Rhee SY; Grant PM; Tzou PL; Barrow G; Harrigan PR; Ioannidis JPA; Shafer RW
J Antimicrob Chemother; 2019 Nov; 74(11):3135-3149. PubMed ID: 31280314
[TBL] [Abstract][Full Text] [Related]
17. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
Fourati S; Charpentier C; Amiel C; Morand-Joubert L; Reigadas S; Trabaud MA; Delaugerre C; Nicot F; Rodallec A; Maillard A; Mirand A; Jeulin H; Montès B; Barin F; Bettinger D; Le Guillou-Guillemette H; Vallet S; Signori-Schmuck A; Descamps D; Calvez V; Flandre P; Marcelin AG;
J Antimicrob Chemother; 2015 May; 70(5):1507-12. PubMed ID: 25558077
[TBL] [Abstract][Full Text] [Related]
18. Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.
Underwood M; Horton J; Nangle K; Hopking J; Smith K; Aboud M; Wynne B; Sievers J; Stewart EL; Wang R
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0164321. PubMed ID: 34694877
[TBL] [Abstract][Full Text] [Related]
19. Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation.
Braun DL; Scheier T; Ledermann U; Flepp M; Metzner KJ; Böni J; Günthard HF
Viruses; 2020 Nov; 12(11):. PubMed ID: 33228206
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis.
Loosli T; Hossmann S; Ingle SM; Okhai H; Kusejko K; Mouton J; Bellecave P; van Sighem A; Stecher M; d'Arminio Monforte A; Gill MJ; Sabin CA; Maartens G; Günthard HF; Sterne JAC; Lessells R; Egger M; Kouyos RD
Lancet HIV; 2023 Nov; 10(11):e733-e741. PubMed ID: 37832567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]